Condition:   Spinal Cord Injury
Interventions:   Device: ReJoyce Workstation;   Other: Standard Care
Sponsors:   University of Melbourne;   Victorian Neurotrauma Initiative;   Life Time Care and Support Authority (NSW);   University of Western Australia
Recruiting - verified March 2010

Condition:   HIV Prevention
Intervention:   Drug: Raltegravir
Sponsors:   St Vincent's Hospital, Sydney;   Merck
Not yet recruiting - verified March 2010

Conditions:   Chronic Medical Conditions;   Personal Health Records;   Electronic Medical Record
Interventions:   Device: Electronic (USB) Portable Health File;   Device: Paper Portable Health File
Sponsors:   St George Hospital, Australia;   South Eastern Area Health Service;   The University of New South Wales;   National Health and Medical Research Council, Australia
Not yet recruiting - verified March 2009

Condition:   Cardiovascular Disease
Interventions:   Drug: Active Clonidine;   Drug: Placebo Clonidine;   Drug: Active ASA;   Drug: Placebo ASA
Sponsor:   Hamilton Health Sciences
Not yet recruiting - verified March 2010

Conditions:   Breast Cancer;   CYP2D6 Polymorphism
Intervention:   Drug: Tamoxifen
Sponsor:   Sydney West Area Health Service
Not yet recruiting - verified February 2010

Condition:   Hepatocellular Cancer
Intervention:  
Sponsor:   Sydney West Area Health Service
Recruiting - verified February 2010

Conditions:   Metabolic Syndrome;   Hypercholesterolemia
Intervention:   Drug: Metformin
Sponsor:   Sydney West Area Health Service
Recruiting - verified February 2010

Condition:   Cardiovascular Diseases
Interventions:   Drug: polypill;   Drug: Usual cardiovascular medications
Sponsors:   Imperial College London;   European Commission;   Imperial College Healthcare NHS Trust;   Royal College of Surgeons, Ireland;   UMC Utrecht;   The George Institute for International Health India;   Public Health Foundation of India;   The George Institute;   Dr. Reddy's Laboratories Limited
Not yet recruiting - verified March 2010

Conditions:   Influenza;   Respiratory Tract Infections
Intervention:   Drug: Oseltamivir
Sponsors:   Chinese University of Hong Kong;   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Other: questionnaire administration;   Procedure: cognitive assessment
Sponsor:   Medical Research Council
Recruiting - verified February 2010

Condition:   IGA Nephropathy
Interventions:   Drug: Aliskiren;   Drug: Placebo
Sponsor:   Chinese University of Hong Kong
Recruiting - verified January 2010

Condition:   Malignant Melanoma
Interventions:   Drug: ABI-007;   Drug: Dacarbazine
Sponsors:   Abraxis BioScience Inc.;   University of Arizona
Recruiting - verified August 2009

Condition:   Cardiovascular Disease
Interventions:   Drug: active clonidine;   Drug: active ASA;   Drug: Clonidine Placebo;   Drug: ASA Placebo
Sponsors:   McMaster University;   The Physicians' Services Incorporated Foundation;   Canadian Network and Centre for Trials Internationally
Completed - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Co., Ltd.;   Duke University
Recruiting - verified March 2010

Condition:   Head and Neck Cancer
Interventions:   Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified December 2008

Conditions:   Lymphoma;   Neutropenia;   Psychosocial Effects of Cancer and Its Treatment;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amoxicillin-clavulanate potassium;   Drug: ciprofloxacin;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsor:   Clatterbridge Centre for Oncology
Recruiting - verified May 2007

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Procedure: 7800 cGy/39 fractions in 8 weeks;   Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors:   Ontario Clinical Oncology Group (OCOG);   Canadian Institutes of Health Research (CIHR);   Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2010

Condition:   Skin Cancer
Interventions:   Drug: Carboplatin;   Radiation: Radiotherapy
Sponsors:   Trans-Tasman Radiation Oncology Group (TROG);   Princess Alexandra Hospital, Brisbane, Australia;   The Royal Australian and New Zealand College of Radiologists;   The Princess Alexandra Hospital Cancer Collaborative Group
Recruiting - verified September 2009

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Conditions:   Stroke;   Transient Ischemic Attack
Interventions:   Other: folic acid;   Dietary Supplement: Vitamin B6;   Dietary Supplement: Vitamin B12
Sponsors:   VITATOPS;   National Health and Medical Research Council, Australia;   National Heart Foundation, Australia;   Medical Health Research Infrastructure Council, Australia
Completed - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine;   Drug: vincristine sulfate
Sponsors:   European Organization for Research and Treatment of Cancer;   Lymphoma Trials Office;   Groupe d'Etudes de Lymphomes de L'Adulte;   Grup per l'Estudi dels Limfomes de Catalunya i Balears;   NCIC Clinical Trials Group;   Australasian Leukaemia and Lymphoma Group (ALLG);   Nordic Lymphoma Group
Active, not recruiting - verified June 2009

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisolone;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Procedure: allogeneic bone marrow transplantation
Sponsor:   Dutch Childhood Oncology Group
Active, not recruiting - verified October 2006

Conditions:   Leukemia;   Neutropenia
Interventions:   Biological: filgrastim;   Drug: amsacrine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: idarubicin;   Drug: mitoxantrone hydrochloride;   Drug: thioguanine;   Drug: tretinoin;   Procedure: allogeneic bone marrow transplantation;   Procedure: autologous bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsor:   Medical Research Council
Active, not recruiting - verified October 2002

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Drug: nilutamide;   Procedure: orchiectomy;   Radiation: radiation therapy
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   Cancer and Leukemia Group B;   Southwest Oncology Group;   Medical Research Council
Active, not recruiting - verified March 2010